NCT00797810Unknown4 期
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
University of Bologna1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Test of the tolerability and efficacy of new therapy elements to improve remission
研究概览
简要总结
All patients are treated according to the same therapy regimen. Therapy duration (number of cycles) and radiotherapy vary according to age group, stage and response. Chemotherapy consists of a pre-phase-treatment (for all patients) and varying A, B and C cycles. Therapy for Patients in the 18-55 Age Group
- Patients in stages III-IV and all patients with mediastinal tumors or extranodal involvement are administered 6 cycles (A1, B1, A2, B2, A3, B3).
- Chemotherapy is stopped after 4 cycles (A1, B1, A2, B2) for patients with stage I/ II if a clear CR has been achieved and there is initially no mediastinal or extranodal involvement.
- In cases of refractory or progressive disease after 4 cycles, study therapy is stopped. These patients are to be given salvage therapy with subsequent stem cell transplantation. Therapy for Patients older than 55 years
- The course corresponds to that of patients in the younger age group, but the regimen is dose reduced (A1*, B1*,A2*, B2*, A3*, B3*). Antibody therapy with anti-CD20 is to be administered on day 1 of each chemotherapy cycle (A, B). After end of chemotherapy (6 or 4 cycles) 2 more cycles of anti-CD 20 are to be administered to reach a total number of 8 resp. 6 cycles antibody therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute lymphoblastic leukemia of the mature B-cell type (L3-ALL)
- •High-grade non-Hodgkin's lymphoma of the following subtypes (WHO classification)
- •Burkitt's lymphoma (including atypical Burkitt's lymphoma)
- •Precursor B-lymphoblastic lymphoma
- •Anaplastic large-cell lymphoma (Ki1+, B-, T- oder Null-cell-type)
- •Mediastinal large B-cell-lymphoma (subtype of diffuse large B-cell lymphoma)
- •Age = 18 years
- •Patient's Informed Consent
排除标准
- •Serious complications caused by leukemia/ lymphoma or by a second illness: e.g.
- •Severe, unmanageable complications such as sepsis, pneumonia with oxygen deficiency,
- •Shock, hemorrhage at the time of diagnosis
- •Renal insufficiency from leukemia/lymphoma-unrelated causes
- •Severe cardiac or hepatic insufficiency
- •Severe obstructive or restrictive lung disease that would compromise patient's treatment with intensified chemotherapy
- •HIV infection
- •Secondary lymphoma following prior chemotherapy/ radiotherapy or an active second malignancy
- •Known severe allergy to foreign proteins
- •Cytostatic pretreatment for B-ALL/lymphoma (exceptions: short-term administration of steroids = 7 days, single administration of vincristine or cyclophosphamide, one cycle of CHOP, a single administration in an emergency of other cytostatic agents) for another malignant disease within the last 5 years
- •Pregnancy/ nursing period
- •Severe psychiatric illness or other circumstances giving ground to the assumption that a patient cannot give his consent to therapy or act co-operatively
- •Absence of patient's informed consent
- •Participation in another clinical study that would possibly interfere with study therapy
研究组 & 干预措施
therapy
Experimental
干预措施: Rituximab (Drug)
结局指标
主要结局
Test of the tolerability and efficacy of new therapy elements to improve remission
Rates, overall survival and remission duration
Administration of anti-CD20 (rituximab ®) together with combination chemotherapy
Combination therapy with high-dose methotrexate and high-dose cytarabine together with conventional cytostatic agents (cycle C)
Prophylactic administration of G-CSF after every cycle of chemotherapy
Localised irradiation after 6 cycles in mediastinal tumor cases, CNS involvement and residual tumor
次要结局
- Test of the age-adapted therapy stratification according to biological age
- (18< age <55)
- Definition of prognostic factors
- Setting up of a central reference pathology panel
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
HEMOS ALL 0105 Intensification therapy of mature B-ALL, Burkitt and Burkitt like and other HIgh Grade Non-Hodgkin?s Lymphoma in Adults - HEMOS ALL 1105B-ALL, Burkitt and Burkitt likeand Non-Hodgkin?s Lymphoma in AdultsMedDRA version: 9.1Level: LLTClassification code 10006595Term: Burkitt's lymphomaEUCTR2006-006154-97-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
已完成
4 期
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in AdultsBurkitt's LeukemiaMediastinal NeoplasmsLymphoblastic LymphomaLarge Cell Anaplastic LymphomaBurkitt's LymphomaNCT00199082Nicola Goekbuget650
已完成
不适用
Treatment Intensification Based on Disease Activity Parameters or on Cartilage Breakdown Markers in Early Rheumatoid Arthritis.NL-OMON2849940
Unknown
2 期
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Mature B-Cell Leukemia Burkitt TypeBurkitt Lymphoma (BL)Unclassifiable Lymphoma Between DCBL and BLNCT05049473PETHEMA Foundation100
招募中
不适用
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in AdultsAcute Lymphoblastic LeukemiaNCT04179929PETHEMA Foundation300